Inpatient hospital costs of febrile neutropenia as a consequence of chemotherapy for breast cancer and Non-Hodgkin lymphoma in Switzerland
Beschreibung
Febrile neutropenia (FN) can be a serious complication of chemotherapy (CHT), increasing mortality risk and healthcare costs. Incidence and inpatient hospital costs of FN in Switzerland are currently not reported. The study aims to: 1. Estimate the number of CHT induced FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in Switzerland.
Eckdaten
Projektleitung
Dr. Renato Mattli, Mark Pletscher
Projektteam
Prof. Dr. Klaus Eichler, Prof. Dr. Simon Wieser
Projektpartner
Amgen Switzerland AG
Projektstatus
abgeschlossen, 10/2012 - 12/2013
Institut/Zentrum
Winterthurer Institut für Gesundheitsökonomie (WIG)
Drittmittelgeber
Dritte